TOFU

Mimecast: The 5 Types of Email Encryption

Retrieved on: 
Thursday, May 19, 2022
Transfer, Bitcoin, GPG, STRIPTLS, PGP, Internet, Diving, POW, 2017 cyberattacks on Ukraine, GNU Privacy Guard, MTA-STS, S/MIME, MTA, Time, TLS, Transport layer, Bitmessage, DANE, STARTTLS, TOFU, GLOBE, Internet service provider, Computer data storage, Mail, Cryptocurrency

Today, there are five main types of email encryption, which fall into two distinct categories.

Key Points: 
  • Today, there are five main types of email encryption, which fall into two distinct categories.
  • This constitutes the most affordable type of email encryption but is slightly less secure than end-to-end.
  • The most widely used and, arguably, the most important protocols in end-to-end encrypted email, PGP and S/MIME can be found within many email clients.
  • While STARTTLS can be a great baseline for email encryption, it is possible to add further layers of protection while messages are in transit.

RIBOMIC Inc. Provides Update on RBM-007 Program in Wet Age-Related Macular Degeneration

Retrieved on: 
Wednesday, March 23, 2022
Health, Clinical Trials, Research, Science, Pharmaceutical, Optical, Biotechnology, IST, Company, Blood, Advertising, Therapy, TOFU, AMD, OCT, Doctor of Philosophy, Standard of care, CEO, Retina, Visual acuity, Safety, Retinal degeneration, CST, Severe cognitive impairment, Growth factor, FGF2, Fibrosis, Patient, Choroidal neovascularization, Pharmaceutical industry, Medical imaging, RBM-007, WET AGE-RELATED MACULAR DEGENERATION

At month 3, the subject gained 12 letters and the subjects BCVA continued to improve without further treatment.

Key Points: 
  • At month 3, the subject gained 12 letters and the subjects BCVA continued to improve without further treatment.
  • RBM-007 provides a unique approach to the treatment of wet AMD with clinically relevant and meaningful improvements in some subjects with nave wet AMD.
  • Wet (exudative) age-related macular degeneration, is the leading cause of blindness in the United States and Europe.
  • "RIBOMIC," "RiboART system" and the RIBOMIC logo are registered trademarks or trademarks of RIBOMIC Inc. in various jurisdictions.

RIBOMIC Announces Preliminary Topline Data From Phase 2 Trials of RBM-007 for Wet Age-Related Macular Degeneration

Retrieved on: 
Tuesday, December 28, 2021
Health, Clinical Trials, Research, Science, Pharmaceutical, Optical, Biotechnology, Data, Growth factor, Company, Retina, Fibrosis, FGF2, Standard of care, Choroidal neovascularization, Safety, Therapy, Patient, Severe cognitive impairment, Advertising, Blood, Retinal degeneration, Pharmaceutical industry, TOFU, RBM-007, wet Age-related Macular Degeneration, RBM-007, WET AGE-RELATED MACULAR DEGENERATION

The company is planning to share the detailed results together with those from its RAMEN extension study and TEMPURA study as full dataset.

Key Points: 
  • The company is planning to share the detailed results together with those from its RAMEN extension study and TEMPURA study as full dataset.
  • The dual action of RBM-007 (anti-angiogenic and anti-scarring) holds promise as an additive or alternative therapy to anti-VEGF treatments for wAMD.
  • Wet (exudative) age-related macular degeneration, is the leading cause of blindness in the United States and Europe.
  • "RIBOMIC," "RiboART system" and the RIBOMIC logo are registered trademarks or trademarks of RIBOMIC Inc. in various jurisdictions.

RIBOMIC Announces Presentation of Masked Preliminary Interim Data from Phase 2 Trials of RBM-007 for Wet Age-Related Macular Degeneration at the Retina Society 2021 Meeting

Retrieved on: 
Thursday, September 30, 2021
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, Retina, Severe cognitive impairment, Advertising, Retinal degeneration, Therapy, Patient, AMD, Data, Choroidal neovascularization, Standard of care, Standards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People, CEO, Growth factor, Company, Standard, FGF2, JST, AES, Injection, Blood, Safety, Fibrosis, Uniloc USA, Inc. v. Microsoft Corp., TOFU, AE, Pharmaceutical industry, Medical device, RBM-007, wet Age-related Macular Degeneration, RBM-007, WET AGE-RELATED MACULAR DEGENERATION

The TOFU study remains masked and all of the interim data from the trial are on a masked basis (RBM-007 arm, RBM-007+Eylea arm, and Eylea arm combined).

Key Points: 
  • The TOFU study remains masked and all of the interim data from the trial are on a masked basis (RBM-007 arm, RBM-007+Eylea arm, and Eylea arm combined).
  • The remainder of the subjects are at different time-points in the trial depending on their start date.
  • Wet (exudative) age-related macular degeneration, is the leading cause of blindness in the United States and Europe.
  • "RIBOMIC," "RiboART system" and the RIBOMIC logo are registered trademarks or trademarks of RIBOMIC Inc. in various jurisdictions.